Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17526592 | 1.00 | KCNH2 (0.43) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL13407598 | 1.00 | KCNH2 (0.43) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL13407592 | 1.00 | KCNH2 (0.43) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL12560583 | 0.98 | KCNH2 (0.40) | KCNH2DNM1PLA2G1BPLA2G2A | |
| SCHEMBL9278295 | 0.91 | CA12 (0.35) | KCNH2PLA2G1BPLA2G2A | |
| SCHEMBL14983628 | 0.88 | DNM1 (0.42) | KCNH2DNM1PLA2G1BPLA2G2ATSHR | |
| SCHEMBL21015388 | 0.84 | SIGMAR1 (0.37) | KCNH2 | |
| SCHEMBL17523780 | 0.84 | SIGMAR1 (0.37) | KCNH2 | |
| SCHEMBL17523765 | 0.84 | SIGMAR1 (0.37) | KCNH2 | |
| SCHEMBL15383401 | 0.84 | SIGMAR1 (0.37) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | KCNH2 3628/4885DNM1 3016/4885PLA2G1B 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.